Research Signal – Source date 2024-02-01
Cellular senescence was first described in the early 1960s, when researchers observed sustained cell-cycle arrest after repeated subculturing of human primary cells. More than half a century later, the subject has become a major part of aging research.
A February 2024 review, Past and Future Directions for Research on Cellular Senescence, surveys major milestones, current challenges, and future research directions. If senescent cells contribute to disease or age-related dysfunction in some settings, should researchers try to remove them, or should they leave the cells in place and reduce the signals they release? The two strategies act on different parts of the biology, and both raise questions about how to identify the right cells and reach them safely.
Senescence is a lasting pause with changing biology
Cellular senescence involves a sustained halt in cell division. That arrest is an important defining feature, but it does not mean that every senescent cell behaves identically or becomes biologically inactive.
Senescence can be triggered by replicative exhaustion, radiation, oncogene activation, genotoxic drugs, oxidative stress, metabolic dysfunction, infection, inflammation, mechanical stress, and developmental signals. Different triggers can produce different forms of senescence. The properties of the resulting cells can also change with their tissue environment and with the stage of the process.
One important feature is the senescence-associated secretory phenotype, often shortened to SASP. This describes substances that senescent cells release into their surroundings, including signaling factors that can influence nearby cells and tissues. Senescent cells and these secretions can have physiological roles in some contexts and pathological roles in others.
That combination creates the central treatment challenge. A cell that has stopped dividing may still be participating in tissue biology, and the same broad category can include cells with different origins, triggers, secretions, and consequences. A useful intervention therefore has to address more than the fact that division has stopped.
Two interventions act on different problems
Senolytics seek to eliminate susceptible senescent cells. The approach is based partly on the observation that some senescent cells rely on senescent cell antiapoptotic pathways, or SCAPs, to avoid cell death. Interfering with those survival pathways may push the targeted cells into apoptosis. In simple terms, a senolytic strategy changes the number of senescent cells by trying to remove cells that depend on particular survival mechanisms.
Senomorphics, also called senostatics, take a different route. They do not aim to kill the senescent cell. Instead, they reduce the release of SASP factors by interfering with regulatory pathways, or blunt their effects by neutralizing individual secreted factors. The review discusses pathways including p38-MAPK, NF-κB, mTOR, and JAK/STAT3, as well as antibodies directed at specific factors.
The distinction is functional rather than merely terminological. Senolytics target the cell’s continued survival; senomorphics target the cell’s effects on its surroundings. A senomorphic intervention could leave a senescent cell present while reducing some of the signals it sends. Because the cell remains, maintaining the effect may require more continuous exposure, and some secretion-suppressing drugs may not be specific to senescent cells.
Neither mechanism is established here as the clinically superior choice. The useful comparison is that they pose different biological and engineering problems. Removing cells requires identifying cells that can be selectively eliminated. Suppressing their secretions requires controlling harmful signaling without assuming that every secretion, or every senescent cell, has the same role.
Markers can reveal a pattern without defining every cell
Testing either strategy in people depends on knowing what is present in a tissue and how it changes after an intervention. That is difficult because the most widely used senescence markers are imperfect. Common examples include SA-β-gal and the cell-cycle inhibitors p16INK4a and p21CIP1/WAF1. The review notes that these markers are neither fully sensitive nor fully specific.
A marker can therefore indicate part of a senescence-associated pattern without providing a universal identity test. A cell may not display the expected marker at every stage, while marker expression by itself may not establish that the cell has the full biological state researchers intend to target. Interpretation becomes even harder when the relevant cells are distributed across different organs, arise from different stresses, or change over time.
Human tissue observations illustrate the issue without resolving it. Senescence-associated markers have been observed in tissues affected by aging and disease. At the same time, accumulation in healthy older people can be slight, while older people with frailty and multiple illnesses may have a higher senescent-cell burden. Those observations can help researchers investigate where senescence-related biology is involved, but they do not by themselves show that removing or modifying the cells will improve a person’s health.
The review points toward more precise measurements across cell types, organs, health conditions, and the life span. Single-cell technologies could allow researchers to examine DNA methylation, chromatin accessibility, messenger RNA, and protein expression together at cellular resolution. Combining those measurements may help distinguish senescent-cell subtypes and clarify what they do in particular tissues. It may also help identify molecular targets for future interventions.
A plausible target still has to reach the right cell
Targeted protein degradation offers one concrete example of the gap between a molecular idea and a treatment that works in the body. A proteolysis-targeting chimera, or PROTAC, is designed as a linked molecule with one ligand that recognizes a chosen protein and another that recruits an E3 ubiquitin ligase. The resulting arrangement can bring the target protein to the cell’s ubiquitin–proteasome system for degradation.
If the selected protein is part of a survival pathway on which certain senescent cells depend, degrading it could promote death in those cells. The proposed action is specific enough to illustrate why targeted degradation is attractive: rather than broadly affecting a cell, the strategy is built around removing a particular protein that may help the cell persist.
The same design also shows why molecular specificity is only one part of the challenge. PROTACs are relatively large molecules, and the review identifies pharmacokinetic and pharmacodynamic questions that must be addressed for efficient delivery in vivo. A candidate must reach the relevant tissue, encounter the intended cell, engage the intended protein, and produce the desired effect at a usable exposure. A plausible mechanism in a controlled experiment does not establish that this sequence will occur reliably in people.
The question is similar for secretion-suppressing approaches, although the target is different. Researchers must determine which signals matter in a particular context and whether they can be reduced without disrupting useful physiology elsewhere. Better markers, spatial information, and time-resolved measurements are therefore not separate from treatment development. They help define what the intervention is supposed to change.
What targeting senescent cells could mean for healthier aging
The longer-term possibility is not universal rejuvenation or a demonstrated extension of human life. It is the more specific prospect that interventions could help older people retain physical or cognitive function and independence for longer by controlling senescence-related effects in the tissues where they matter.
That prospect remains conditional. Researchers would need to identify the relevant cells and signals, reach them with an intervention that behaves as intended, control harmful effects without disrupting beneficial roles, and demonstrate meaningful benefit with acceptable safety in people. If those links are established, senolytic and senomorphic strategies could contribute to more healthy years of life. The review’s value is in showing why that path depends on connecting mechanism, measurement, and delivery rather than treating a senescence marker or a promising molecular target as proof of benefit.
Key Sources
- Primary source: Past and Future Directions for Research on Cellular Senescence.
DOI or Journal Page · Review or Meta-Analysis · 2024-02-01
Keep exploring